Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antje M Wengner

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
International Journal of Molecular Sciences|November 7, 2020
Targeting DNA Damage Response in Prostate and Breast CancerAntje M Wengner, Arne Scholz, Bernard Haendler
Blood|October 12, 2007
The coordinated action of G-CSF and ELR + CXC chemokines in neutrophil mobilization during acute inflammationAntje M Wengner, Simon C Pitchford, Rebecca C Furze, et al.
Cell Stem Cell|January 9, 2009
Differential mobilization of subsets of progenitor cells from the bone marrowSimon C Pitchford, Rebecca C Furze, Carla P Jones, et al.
Molecular Cancer Therapeutics|July 24, 2012
BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral applicationGerhard Siemeister, Ulrich Lücking, Antje M Wengner, et al.
Blood|October 5, 2006
CCR7 deficiency causes ectopic lymphoid neogenesis and disturbed mucosal tissue integrityUta E Höpken, Antje M Wengner, Christoph Loddenkemper, et al.
Arthritis and Rheumatism|October 2, 2007
CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritisAntje M Wengner, Uta E Höpken, Peter K Petrow, et al.
Frontiers in Medicine|February 2, 2023
Targeted thorium-227 conjugates as treatment options in oncologyJenny Karlsson, Christoph A Schatz, Antje M Wengner, et al.
Cancer Letters|January 4, 2017
BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activitySusann Santag, Franziska Siegel, Antje M Wengner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
Synergistic Effect of a Mesothelin-Targeted <sup>227</sup>Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft ModelsKatrine Wickstroem, Urs B Hagemann, Véronique Cruciani, et al.
Cancer Cell|January 11, 2017
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKTJuliane Paul, Maurice Soujon, Antje M Wengner, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
International Journal of Molecular Sciences|November 7, 2020
Targeting DNA Damage Response in Prostate and Breast CancerAntje M Wengner, Arne Scholz, Bernard Haendler
Blood|October 12, 2007
The coordinated action of G-CSF and ELR + CXC chemokines in neutrophil mobilization during acute inflammationAntje M Wengner, Simon C Pitchford, Rebecca C Furze, et al.
Cell Stem Cell|January 9, 2009
Differential mobilization of subsets of progenitor cells from the bone marrowSimon C Pitchford, Rebecca C Furze, Carla P Jones, et al.
Molecular Cancer Therapeutics|July 24, 2012
BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral applicationGerhard Siemeister, Ulrich Lücking, Antje M Wengner, et al.
Blood|October 5, 2006
CCR7 deficiency causes ectopic lymphoid neogenesis and disturbed mucosal tissue integrityUta E Höpken, Antje M Wengner, Christoph Loddenkemper, et al.
Arthritis and Rheumatism|October 2, 2007
CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritisAntje M Wengner, Uta E Höpken, Peter K Petrow, et al.
Frontiers in Medicine|February 2, 2023
Targeted thorium-227 conjugates as treatment options in oncologyJenny Karlsson, Christoph A Schatz, Antje M Wengner, et al.
Cancer Letters|January 4, 2017
BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activitySusann Santag, Franziska Siegel, Antje M Wengner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
Synergistic Effect of a Mesothelin-Targeted <sup>227</sup>Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft ModelsKatrine Wickstroem, Urs B Hagemann, Véronique Cruciani, et al.
Cancer Cell|January 11, 2017
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKTJuliane Paul, Maurice Soujon, Antje M Wengner, et al.
Pageof 3